Novo Nordisk to Limit Semaglutide Sales in China Amid Global Supply Concerns

Novo Nordisk's International Business Director, Du Maike, stated that the company will limit the sales of its blockbuster weight-loss drug Wegovy (brand name: Novo Ying) in China to prevent an influx of Chinese patients from causing a drug shortage in other parts of the world. (Cailian Press)Original Link